ROI

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

For the second year, Southwest Gas has been named a top company by TIME. We explore the strategy behind its success in culture, growth, and sustainability.

A new partnership shows how data-driven onsite health centers are slashing hospital bills and improving patient outcomes, offering a new playbook for employers.

With $10M in revenue and major institutional backing, Safe Project is proving that crypto infrastructure can be a sustainable business without token subsidies.

Genspark's 'Call for Me' AI automates tasks via phone calls, but this new convenience raises complex questions about efficiency, ethics, and the future of work.

With new funding, Mitra EV is removing the upfront cost barrier, making electric fleets an immediate money-saver for businesses of all sizes.

New data reveals small businesses are leveraging AI-powered PCs to compete with corporate giants, driving a fundamental shift in productivity and strategy.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

The tech giant's recent accolades for innovation, ethics, and leadership hint at a future where AI is both powerful and responsible for nonprofits.

A new feature sends a compliant text moments before an AI call, promising to boost connection rates, enhance revenue, and rebuild trust in sales outreach.

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

As the hospitality sector faces headwinds, a Philadelphia wine school is hiring and shifting to deeper, semester-long courses to meet surging demand.

A legacy manufacturer turned decades of dormant engineering files into a strategic asset, recovering 600 hours and boosting efficiency by 98% with AI.

As CFO Mike Santomassimo prepares for the UBS conference, investors seek clarity on Wells Fargo's strategy after its asset cap removal and rate cut impacts.

An independent analysis shows a specialized OB/GYN staffing model improves maternal outcomes, lowers C-section rates, and delivers a significant return on investment.

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.